DDrare: Database of Drug Development for Rare Diseases

283. 後天性赤芽球癆
［臨床試験数：17，薬物数：36（DrugBank：19），標的遺伝子数：16，標的パスウェイ数：91］

Searched query = "Acquired pure red cell aplasia", "Pure red cell aplasia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AF37702 Injection; AF37702, Hematide; Alemtuzumab; Anti-thymocyte globulin; Bortezomib; Bortezomib/dexamethasone; Campath; Campath, Chemo and/or TBI Allo SCT; Cyclophosphamide; Cyclophosphamide + pred; Cyclosporine; Cyclosporine A; Cyclosporine combine with mycophenolate mofetil; Daclizumab; Dexamethasone; Filgrastim; Fludarabine; Fludarabine Phosphate; Hematide; Hematide, peginesatide; Leucine; Methylprednisolone; Mycophenolate; Mycophenolate mofetil; Other: Laboratory Biomarker Analysis; Peginesatide; Phosphate; Prednisone; Procedure: Autologous Peripheral Blood Stem Cell Transplantation; Procedure: Peripheral Blood Stem Cell Transplantation; Radiation: Total Body Irradiation; Radiation: Total-Body Irradiation; Rituximab; Sirolimus; Tacrolimus; Trifluoperazine

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04470804 (ClinicalTrials.gov)	August 1, 2020	9/7/2020	Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA	Sirolimus Treatment for Newly Diagnosed Primary Acquired Pure Red Cell Aplasia: a Single Center Prospective Study	Pure Red Cell Aplasia, Acquired	Drug: Sirolimus;Drug: Cyclosporine A	Bing Han	NULL	Not yet recruiting	18 Years	70 Years	All	40	Phase 4	China
2	NCT03364764 (ClinicalTrials.gov)	January 2018	21/11/2017	Sirolimus Treatment for Refractory PRCA	Sirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study	Pure Red Cell Aplasia	Drug: Sirolimus	Bing Han	NULL	Recruiting	18 Years	80 Years	All	30	Phase 4	China
3	NCT03214354 (ClinicalTrials.gov)	July 5, 2017	5/7/2017	Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor	A Phase II Pilot Study of Nonmyeloablative Conditioning Hematopoietic Stem Cell Transplantation in Children With Sickle Cell Disease Who Have a Matched Related Major ABO-Incompatible Donor (Sickle-MAID)	Sickle Cell Disease;Stem Cell Transplant Complications;Red Blood Cell Disorder;Pure Red Cell Aplasia	Drug: Alemtuzumab;Radiation: Total Body Irradiation;Drug: Sirolimus	University of Calgary	NULL	Recruiting	1 Year	19 Years	All	12	Phase 2	Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04470804
(ClinicalTrials.gov)

August 1, 2020

9/7/2020

Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA

Sirolimus Treatment for Newly Diagnosed Primary Acquired Pure Red Cell Aplasia: a Single Center Prospective Study

Pure Red Cell Aplasia, Acquired

Drug: Sirolimus;Drug: Cyclosporine A

Bing Han

NULL

Not yet recruiting

18 Years

70 Years

All

Phase 4

China

NCT03364764
(ClinicalTrials.gov)

January 2018

21/11/2017

Sirolimus Treatment for Refractory PRCA

Sirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study

Pure Red Cell Aplasia

Drug: Sirolimus

Bing Han

NULL

Recruiting

18 Years

80 Years

All

Phase 4

China

NCT03214354
(ClinicalTrials.gov)

July 5, 2017

5/7/2017

Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor

A Phase II Pilot Study of Nonmyeloablative Conditioning Hematopoietic Stem Cell Transplantation in Children With Sickle Cell Disease Who Have a Matched Related Major ABO-Incompatible Donor (Sickle-MAID)

Sickle Cell Disease;Stem Cell Transplant Complications;Red Blood Cell Disorder;Pure Red Cell Aplasia

Drug: Alemtuzumab;Radiation: Total Body Irradiation;Drug: Sirolimus

University of Calgary

NULL

Recruiting

1 Year

19 Years

All

Phase 2

Canada